Imexpharm Statistics

Total Valuation

Imexpharm has a market cap or net worth of VND 7.44 trillion. The enterprise value is 7.27 trillion.

Market Cap	7.44T
Enterprise Value	7.27T

Important Dates

The next estimated earnings date is Friday, January 17, 2025.

Earnings Date	Jan 17, 2025
Ex-Dividend Date	Jul 11, 2024

Share Statistics

Imexpharm has 154.01 million shares outstanding. The number of shares has increased by 0.00% in one year.

Current Share Class	n/a
Shares Outstanding	154.01M
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	+7.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.64%
Float	n/a

Valuation Ratios

The trailing PE ratio is 32.40 and the forward PE ratio is 24.08.

PE Ratio	32.40
Forward PE	24.08
PS Ratio	3.44
PB Ratio	3.46
P/TBV Ratio	3.58
P/FCF Ratio	46.88
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 15.78, with an EV/FCF ratio of 45.84.

EV / Earnings	31.67
EV / Sales	3.36
EV / EBITDA	15.78
EV / EBIT	20.39
EV / FCF	45.84

Financial Position

The company has a current ratio of 3.40, with a Debt / Equity ratio of 0.05.

Current Ratio	3.40
Quick Ratio	1.46
Debt / Equity	0.05
Debt / EBITDA	0.23
Debt / FCF	0.66
Interest Coverage	110.78

Financial Efficiency

Return on equity (ROE) is 13.10% and return on invested capital (ROIC) is 10.26%.

Return on Equity (ROE)	13.10%
Return on Assets (ROA)	8.80%
Return on Capital (ROIC)	10.26%
Revenue Per Employee	1.49B
Profits Per Employee	158.80M
Employee Count	1,415
Asset Turnover	0.85
Inventory Turnover	1.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +86.42% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+86.42%
50-Day Moving Average	45,239.00
200-Day Moving Average	39,306.75
Relative Strength Index (RSI)	59.23
Average Volume (20 Days)	284,415

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imexpharm had revenue of VND 2.16 trillion and earned 229.63 billion in profits. Earnings per share was 1,490.89.

Revenue	2.16T
Gross Profit	968.64B
Operating Income	356.70B
Pretax Income	343.33B
Net Income	229.63B
EBITDA	460.80B
EBIT	356.70B
Earnings Per Share (EPS)	1,490.89

Full Income Statement

Balance Sheet

The company has 270.41 billion in cash and 104.19 billion in debt, giving a net cash position of 166.23 billion or 1,079.33 per share.

Cash & Cash Equivalents	270.41B
Total Debt	104.19B
Net Cash	166.23B
Net Cash Per Share	1,079.33
Equity (Book Value)	2.15T
Book Value Per Share	13,960.70
Working Capital	1.04T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 239.21 billion and capital expenditures -80.55 billion, giving a free cash flow of 158.66 billion.

Operating Cash Flow	239.21B
Capital Expenditures	-80.55B
Free Cash Flow	158.66B
FCF Per Share	1,030.18

Full Cash Flow Statement

Margins

Gross margin is 44.82%, with operating and profit margins of 16.50% and 12.61%.

Gross Margin	44.82%
Operating Margin	16.50%
Pretax Margin	15.89%
Profit Margin	12.61%
EBITDA Margin	21.32%
EBIT Margin	16.50%
FCF Margin	7.34%

Dividends & Yields

This stock pays an annual dividend of 454.55, which amounts to a dividend yield of 0.94%.

Dividend Per Share	454.55
Dividend Yield	0.94%
Dividend Growth (YoY)	10.00%
Years of Dividend Growth	n/a
Payout Ratio	50.14%
Buyback Yield	-0.00%
Shareholder Yield	0.94%
Earnings Yield	3.09%
FCF Yield	2.13%

Dividend Details

Stock Splits

The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.

Last Split Date	Sep 17, 2024
Split Type	Forward
Split Ratio	2

Scores

Imexpharm has an Altman Z-Score of 8.99.

Altman Z-Score	8.99
Piotroski F-Score	n/a